DC
AURA icon

Decheng Capital’s Aura Biosciences AURA Stock Holding History

Decheng Capital’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-360,483
Closed -$1.96M – 15
2025
Q4 		$1.96M Sell
360,483
-155,072
-30% -$921K 0.26% 14
2025
Q3 		$3.19M Hold
515,555
– – 0.56% 15
2025
Q2 		$3.23M Hold
515,555
– – 0.82% 15
2025
Q1 		$3.02M Hold
515,555
– – 0.85% 19
2024
Q4 		$4.24M Hold
515,555
– – 0.91% 21
2024
Q3 		$4.59M Hold
515,555
– – 1.09% 15
2024
Q2 		$3.9M Hold
515,555
– – 1.19% 16
2024
Q1 		$4.05M Hold
515,555
– – 0.54% 17
2023
Q4 		$4.57M Buy
+515,555
New +$4.37M 1.28% 16

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Decheng Capital's AURA Position: Q1 2026 in Review

Decheng Capital sold out of Aura Biosciences (AURA) in Q1 2026, closing a stake of 360,483 shares — an estimated $1.96M sold.

Decheng Capital first reported a position in AURA in Q4 2023 and held it in 9 quarters. The position peaked at $4.59M in Q3 2024. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Decheng Capital reported no remaining Aura Biosciences position as of Q1 2026 after selling out during the quarter.
  • Decheng Capital sold 360,483 Aura Biosciences shares in Q1 2026, an estimated $1.96M.
  • Decheng Capital first reported a position in Aura Biosciences in Q4 2023 and held it in 9 quarters.
  • Decheng Capital's Aura Biosciences position peaked at $4.59M in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Decheng Capital's 13F filing for Q1 2026, filed 13 May 2026.